These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1161 related items for PubMed ID: 15639692

  • 1. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR, Frei CR, Burgess DS.
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
    Kiffer CR, Kuti JL, Eagye KJ, Mendes C, Nicolau DP.
    Int J Antimicrob Agents; 2006 Oct; 28(4):340-4. PubMed ID: 16930951
    [Abstract] [Full Text] [Related]

  • 3. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C, Yetkin F, Görgeç S, Ersoy Y.
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [Abstract] [Full Text] [Related]

  • 4. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG, Pozdirca M, Golden AR, Lawrence CK, Zelenitsky S, Berry L, Schweizer F, Bay D, Adam H, Zhanel MA, Lagacé-Wiens P, Walkty A, Irfan N, Naber K, Lynch JP, Karlowsky JA.
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [Abstract] [Full Text] [Related]

  • 5. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
    Hernández JR, Velasco C, Romero L, Martínez-Martínez L, Pascual A.
    Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
    [Abstract] [Full Text] [Related]

  • 6. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
    DeRyke CA, Banevicius MA, Fan HW, Nicolau DP.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR, Burgess DS.
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [Abstract] [Full Text] [Related]

  • 8. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
    Mody RM, Erwin DP, Summers AM, Carrero HA, Selby EB, Ewell AJ, Moran KA.
    Ann Clin Microbiol Antimicrob; 2007 Jun 06; 6():6. PubMed ID: 17553151
    [Abstract] [Full Text] [Related]

  • 9. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG, Baudry PJ, Tailor F, Cox L, Hoban DJ, Karlowsky JA.
    J Antimicrob Chemother; 2009 Oct 06; 64(4):824-8. PubMed ID: 19643776
    [Abstract] [Full Text] [Related]

  • 10. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D, Yinnon AM, Broide E, Rudensky B.
    Chemotherapy; 2007 Oct 06; 53(3):185-9. PubMed ID: 17347564
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
    Kiremitci A, Dinleyici EC, Erben N, Durmaz G, Yargic ZA, Aybey AD, Usluer G.
    Expert Opin Pharmacother; 2008 Jun 06; 9(9):1441-9. PubMed ID: 18518776
    [Abstract] [Full Text] [Related]

  • 12. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ, Ullberg M, Bernander S, Ericson E, Larsson P, Rydberg J, Törnqvist E, Melhus A.
    Scand J Infect Dis; 2006 Jun 06; 38(10):853-9. PubMed ID: 17008228
    [Abstract] [Full Text] [Related]

  • 13. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
    Jean SS, Lee WS, Bai KJ, Yu KW, Hsu CW, Yu KW, Liao CH, Chang FY, Ko WC, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Liu CY, Chen RJ, Hsueh PR.
    Diagn Microbiol Infect Dis; 2015 Apr 06; 81(4):290-5. PubMed ID: 25600841
    [Abstract] [Full Text] [Related]

  • 14. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2005 Aug 06; 26(2):120-5. PubMed ID: 16046101
    [Abstract] [Full Text] [Related]

  • 15. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems.
    Vading M, Samuelsen Ø, Haldorsen B, Sundsfjord AS, Giske CG.
    Clin Microbiol Infect; 2011 May 06; 17(5):668-74. PubMed ID: 20649801
    [Abstract] [Full Text] [Related]

  • 16. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
    Tängdén T, Adler M, Cars O, Sandegren L, Löwdin E.
    J Antimicrob Chemother; 2013 Jun 06; 68(6):1319-26. PubMed ID: 23478794
    [Abstract] [Full Text] [Related]

  • 17. [Validity of using imipenem as a representative carbapenems and levofloxacin as a representative fluoroquinolones in antibiotics susceptibility test for enterobacteriaceae].
    Takahashi N, Gomi K, Yamaguchi F, Fukuchi K, Wakuta R.
    Jpn J Antibiot; 2011 Feb 06; 64(1):19-26. PubMed ID: 21612040
    [Abstract] [Full Text] [Related]

  • 18. [In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase].
    Villar HE, Jugo MB, Visser M, Hidalgo M, Hidalgo G, Maccallini GC.
    Rev Esp Quimioter; 2014 Mar 06; 27(1):51-5. PubMed ID: 24676243
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model.
    Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP.
    Antimicrob Agents Chemother; 2005 Jan 06; 49(1):276-80. PubMed ID: 15616306
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region.
    Roberts JA, Kwa A, Montakantikul P, Gomersall C, Kuti JL, Nicolau DP.
    Int J Antimicrob Agents; 2011 Mar 06; 37(3):225-9. PubMed ID: 21168997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.